Janux Therapeutics (NASDAQ:JANX) Stock Price Up 10.2% – Still a Buy?

by · The Cerbat Gem

Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report)’s stock price was up 10.2% on Tuesday . The company traded as high as $34.43 and last traded at $34.7330. Approximately 1,609,294 shares were traded during trading, an increase of 72% from the average daily volume of 937,236 shares. The stock had previously closed at $31.53.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Wedbush reiterated an “outperform” rating and issued a $76.00 target price on shares of Janux Therapeutics in a research note on Friday, November 7th. Wolfe Research assumed coverage on shares of Janux Therapeutics in a research note on Tuesday, November 18th. They issued a “peer perform” rating for the company. Guggenheim began coverage on shares of Janux Therapeutics in a report on Wednesday, September 3rd. They set a “buy” rating and a $72.00 target price on the stock. Wall Street Zen raised Janux Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $70.00 price target on shares of Janux Therapeutics in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $79.17.

Read Our Latest Report on Janux Therapeutics

Janux Therapeutics Stock Performance

The company’s 50 day simple moving average is $26.66 and its 200-day simple moving average is $25.21. The firm has a market capitalization of $2.09 billion, a PE ratio of -20.65 and a beta of 2.83.

Janux Therapeutics (NASDAQ:JANX – Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.21. The firm had revenue of $10.00 million during the quarter, compared to the consensus estimate of $3.07 million. On average, equities research analysts forecast that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Insider Buying and Selling at Janux Therapeutics

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 3,333 shares of the firm’s stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $30.00, for a total value of $99,990.00. Following the sale, the insider owned 84,974 shares of the company’s stock, valued at $2,549,220. This trade represents a 3.77% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 8.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Janux Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. US Bancorp DE grew its stake in Janux Therapeutics by 2,402.9% in the 1st quarter. US Bancorp DE now owns 1,727 shares of the company’s stock worth $47,000 after buying an additional 1,658 shares in the last quarter. Osaic Holdings Inc. lifted its holdings in shares of Janux Therapeutics by 704.6% during the 2nd quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock worth $80,000 after acquiring an additional 3,037 shares during the last quarter. Virtus Investment Advisers LLC lifted its holdings in shares of Janux Therapeutics by 37.9% during the 2nd quarter. Virtus Investment Advisers LLC now owns 3,679 shares of the company’s stock worth $85,000 after acquiring an additional 1,011 shares during the last quarter. Tower Research Capital LLC TRC grew its position in Janux Therapeutics by 175.5% in the second quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock worth $91,000 after acquiring an additional 2,502 shares in the last quarter. Finally, Ameritas Investment Partners Inc. increased its stake in Janux Therapeutics by 25.6% in the second quarter. Ameritas Investment Partners Inc. now owns 4,020 shares of the company’s stock valued at $93,000 after acquiring an additional 820 shares during the last quarter. 75.39% of the stock is owned by hedge funds and other institutional investors.

About Janux Therapeutics

(Get Free Report)

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

Further Reading